Synthesis of novel bifuntional bisphosphonates by Topcu, Ercan
 
 
                                                                                                                                                          
                                                                                          
            
 
            
 
 
 
 
 
 
 
 
 
 SYNTHESIS OF NOVEL BIFUNCTIONAL 
BISPHOSPHONATES 
 
 
 
 
 
Ercan Topçu 
  
 
 
 
 
Master’s thesis 
Department of Chemistry 
Medicinal chemistry 
475/2014 
1 
 
      
       SYNTHESIS OF NOVEL BIFUNCTIONAL BISPHOSPHONATES  
 
       Student: Ercan Topçu (251253) 
       Supervisors: Elina Puljula  
                            Sebahat Ucal 
 
       Abstract 
 
       Bisphosphonates (BPs) are synthetic molecules containing a P-C-P backbone and 
are very well known class of organophosphorus compounds which have many 
applications in different fields of industry. BPs have high affinity for hydroxyapatite 
(HAP), which is the main mineral found in bones, and they can chelate several metal 
ions, such as Mg(II), Ca(II), and Fe(II). BPs are easily taken up by the bone tissue 
where they can prevent the resorption of bone. This makes them crucial to be used in 
the treatment of diseases related with increased bone resorption, for instance 
osteoporosis. The aim of the current research is to show an approach to chemistry 
underlying the properties of novel chealating agents with BP and polyamine (PA) 
moieties. In this study, two novel BP-PA conjugates were prepared and characterized by 
NMR method. This thesis is a part of the investigations based on BPs and their 
functions in pharmaceutical chemistry field. 
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Abbreviations 
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CLO – Clodronate 
DETA – Diethylenetriamine 
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GC – Gas chromatography 
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PAM – Pamidronate 
PPi – Pyrophosphate 
PUT – Putrescine 
RANKL – Receptor activator of nuclear factor-ĸB ligand 
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SAR – Structure-activity relationship 
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1 Bisphosphonates, their derivatives and current 
applications  
 
1.1 Introduction 
 
       The studies in this master thesis are based on bisphosphonates (BPs). Chemically, 
BPs are synthetic analogues of naturally occurring pyrophosphates (P-O-P). The 
simplest type of pyrophosphate molecules naturally found widely in nature is inorganic 
pyrophosphate (PPi). In the case of BP, central carbon atom replaces the oxygen atom 
that has a connection to two phosphates, so that the BP structure contains a P-C-P 
backbone. According to historical development of BPs, they were firstly synthesized 
more than one century ago in 1800s 
[1]
. However, the early use of BPs was mainly as 
complexing agents in textile, oil, and fertilizer industries, as corrosion inhibitors as well 
as for several other industrial aims
 [2]
. 
 
       Utilization of BPs’ additional properties came to light subsequently in 
pharmaceutical chemistry field as well. The turning point of these molecules occurred 
approximately 50 years ago by using them in treatment of disorders of calcium 
metabolism
 [3]
. Even though first BPs were synthesized over a century ago, and that the 
existence of them has been known for a long time, their journey in pharmaceutical field 
initiated with etidronate (ETI) which was the first BP to be used in humans for the 
treatment of calcification disorders, such as myositis ossificans progressive (now known 
as fibrodysplasia ossificans progressiva or FOP).  
 
       Moreover the subject of use of BPs in pharmaceutical industry is currently being 
developed by scientists. Nowadays, the most interesting field for BPs use is the field of 
the treatment of bone related diseases, such as osteoporosis. They can chelate several 
metal ions, such as Mg(II), Ca(II), and Fe(II)
 [4]
. BPs have high affinity to HAP, which 
is the main mineral taking place in bones
 [5]
. BPs are easily taken up from the 
bloodstream by the bone tissue where they can prevent the resorption of bone. Therefore 
BPs are used in the treatment of diseases related with increased bone resorption.  
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       Applications of BPs cannot be narrowed by the fields mentioned above because the 
topic of BPs and their use are significantly a wide field in chemistry. Nowadays, there 
are averagely more than 20 000 publications according to a recent search on several 
databases. These many different research topics about BPs have been mainly based on 
their medical and non-medical applications. Hence this literature overview is intended 
to feature the properties of BPs having interesting usage in many different fields of 
science. 
 
1.2 Historical aspect of development of bisphosphonates 
 
       As mentioned in introduction part before, first BPs were synthesized in 1800s and 
new BPs are still being developed for several purposes. Though BP use in industry and 
its importance are undeniable, this thesis will be mostly focusing on the development of 
medical applications of BPs’ as the research topic is closer to that part of studies.  
 
       Before being used as inhibitors of resorption in the treatment of bone disease, BPs 
were originally thought as inhibitors of calcification 
[6]
. In the earliest studies it was 
proven that BPs could bind to HAP crystals and inhibit crystal growth as PPi also does 
[7, 8]
. The turning point of BPs based on biological studies was the discovery of that, BPs 
inhibit bone resorption
 [9, 10]
.  
 
       From the first clinical use of BPs to present applications, BP studies have been in a 
very long journey of science, especially in pharmaceutical chemistry field. The first 
member of clinical uses of such interesting compounds, BPs, was ETI used in the 
treatment of calcification disorders, such as myositis ossificans progressive 
[11]
. It was 
also the first one to use in order to treat bone resorption when used for the patients with 
Paget’s disease [12]. As BPs have strong affinity to bone mineral, also other studies 
carried out shortly after it was used in bone resorption investigations. BPs were also 
started to be used as therapeutic agents in oncology during 1970s. They then became 
extensively developed for the treatment and prevention of skeletal complications related 
with multiple myeloma or bone metastases arising from cancers of breast, prostate, and 
other organs 
[11]
. Nowadays the field of BPs in use is even wider than it was before. 
7 
 
Moreover there are many available resources, such as, books and articles, concerning 
the chemistry, clinical application and pharmacology of BPs 
[11]
.   
A basic understanding towards the historical development of BPs is shown below 
(Figure 1). 
 
  
  Figure 1. The history of BPs 
[5]
. 
 
1.3 Bisphosphonate structure and the link between bisphosphonate and 
pyrophosphate  
       
     BPs (Figure 2) are synthetic molecules containing a P-C-P backbone and are a class 
of organophosphorous compounds containing two phosphonate groups
 [3]
. As they have 
two phosphonate (PO3) groups, they are called bisphosphonates, bis referring to the two 
similar groups in the compound. They have a very similar structure to pyrophosphate 
(Figure 3) which has a P-O-P structure instead. Pyrophosphates are the most soluble 
ones among the phosphate groups and they are very good complexing agents for metal 
ions, such as Ca
2+
 and Mg
2+
. They have also many uses in industry 
[7, 13]
. 
8 
 
 
 
Figure 2. Basic structure of bisphosphonate. 
 
 
Figure 3. Basic structure of pyrophosphate. 
 
       Alteration in the central atom which is between two phosphorus atoms, changes 
also the name of the compound for pyrophosphate as well as its properties on intended 
applications both in medicine and industry. The nomenclature is specified by presence 
of the groups bound to the central pentavalent atom of phosphorus 
[14]
. 
 
       BP compounds have a central carbon which characterizes the whole compound 
itself. The bond type between the carbon and phosphorus atoms confers upon the 
chemical stability of BPs and their resistance to enzymatic or acid hydrolysis, which 
actually renders the molecule resistant to biological degradation 
[15, 16]
.  Therefore it was 
thought that BPs are not metabolized in the body for a long time. This fact, was literally 
consistent with the observation which they are excreted unaltered. However nowadays 
some of the BPs are already known to be incorporated intracellularly into ATP 
analogues 
[15]
.   
 
       Alongside of these bond abilities, the BP structure also has two groups 
(substituents) attached to geminal carbon. These two side-chains are responsible for 
most of the biological activity observed among the BPs. So basically, altering R1 and R2 
groups can change on the features of BPs 
[17, 18]
. 
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1.4 Classification of bisphosphonates         
 
       Chemically and enzymatically stable analogues of pyrophospates, BPs, can be 
separated into two types based on their structure and mechanism of action. These two 
types of BPs are referred according to their mechanism of action to inhibit bone 
resorption. The one having no nitrogen in its structure is called non-nitrogen-containing 
BP (NNBP), and the one having at least one nitrogen atom in its R1 or R2 groups is 
called nitrogen-containing BP (NBP). NNBPs are incorporated into ATP resulting into 
hydrolysable adenine containing metabolite. NBPs get involved in with the mevalonate 
pathway and they function by inhibiting the farnesyl pyrophosphate (FPP) synthase 
enzyme being responsible for the synthesis of FPP used in protein prenylation, 
cholesterol, ergosterol, heme a, ubiquinone, and dolichol production 
[19, 20]
. NBPs are 
also involved in direct anticancer studies 
[21, 22, 23, 24]
 . 
 
       The BP drugs currently being used in pharmaceutical field in clinics can be 
classified in three generations based on their structure-activity relations. All the 
variations in ability and the potency of the compounds are determined by the properties 
of three-dimensional structure of these two side chains, R1 and R2, connected to the 
central carbon atom 
[25, 26, 27]
. The first-generation, also called simple BPs, includes 
NNBPs which have simple and relatively low potency R1 and R2 groups, such as ETI 
and clodronate (CLO). The second-generation BPs include a primary amine group, and 
have a better potency than the first-generation BPs. Alendronate (ALN), ibandronate 
(IBA) and pamidronate (PAM) are the examples for the group of second-generation 
BPs.  ALN is about 1000-fold more potent than ETI moreover PAM is only 100-fold 
more active than ETI 
[28]
. Affiliation of an aminoalkyl side chain at R2 increases the 
antiresorptive potency, moreover, the length of carbon chain is also significant
 [29, 30, 31, 
32]
. Third-generation BPs are characterized by having a cyclic side chain and in their 
structure the sp2 nitrogen is a part of a heterocyclic ring 
[33]
. Zoledronate (ZOL), 
Minodronate (MIN) and risedronate (RIS) are in the group of third-generation of BPs. 
Incorporation of a nitrogen heterocycle further enhances the potency. The most active 
one among the third-generation BPs, is ZOL. Additionally, ZOL is up to 10000-fold 
more potent than both CLO and ETI in some experimental systems 
[34]
.  
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       The individual profiles of specific BPs mentioned above may relate to their clinical 
characteristics. According to IUPAC recommendations, BPs in acidic forms are called 
with the term of “phosphonic acid” which structurally equals to (HP(O)(OH)2).  
However, almost all of the BPs in clinical use are actually in their salt form. They are 
therefore called by the names of their salt forms, such as CLO, ETI or ALN. In the 
literature part of this thesis, the BPs in clinical use are called in the way mentioned 
above.  
 
1.5 Structure– activity relationships of bisphosphonates 
 
       Structure-activity relation (SAR) is almost always one of the key points in any kind 
of research in pharmaceutical chemistry field. There are two main features playing an 
important role on the ability of the BPs to inhibit bone resorption 
[35, 18]
. The first feature 
is the high affinity to bone mineral 
[36, 37, 38]
  and the second feature is the structure of 
side chains, R1 and R2 
[39]
. 
       The antiresorptive potency of a BP depends on the side chains, R1 and R2 groups, 
attached to geminal carbon of the P-C-P moiety. The P-C-P moiety of BP plays an 
important role for the strong affinity of BPs for binding to HAP. Furthermore, the 
ability of BPs to inhibit bone resorption requires the structure of P-C-P acting as “bone 
hook” [5]. The compounds containing P-C-C-P and P-N-P structures are ineffective to 
inhibit the resorption of bone. As discussed earlier in the literature part, altering of the 
R1 and R2 substituents in BP molecule, creates a number of variations in the structure of 
BP. R2 groups have their own unique effect on antiresorptive potency and this case is 
thought to be mediated to the ability to affect biochemical activity 
[40, 41, 42]
. 
        The affinity of BPs for calcium is even better when there is a hydroxyl group at the 
side chain of the R1 group because then chelating occurs by tridentate binding 
[38]
. BPs 
can chelate calcium ions also by bidentate binding via the oxygen atoms. 
       Alteration in the structure of heterocyclic R2 group attached to P-C-P moiety, can 
significantly affect the antiresorptive potency of the BP compound 
[43, 44]
. It is also 
stated that the mechanism of action of BPs includes a stereo-specific interaction of the 
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side chains, especially on R2, in its structure
 [18]
. For reaching the maximum potency, the 
nitrogen atom in the R2 side chain has to be both in an optimum distance with the P-C-P 
moiety and in a specific spatial configuration
 [45]
.  
       To sum up, modifications to both or either of the phosphonate groups, such as 
substitution of P-C-P bonds, replacement of hydroxyl group, and the removal of one of 
the phosphonate groups, reduce the antiresorptive potency 
[10, 39]
. The results concerning 
the reduction in antiresorptive potency are not always due to the loss in affinity for bone 
and it is also known that both of the phosphonate groups in the structure of BPs are 
crucial for a drug to be pharmacologically active 
[46, 5]
. However, so far no biochemical 
mechanism has been presented to explain the SAR of BPs as a whole. Therefore, there 
might be a need for molecular interaction model for BPs with their pharmacological 
targets.       
 
1.6 Pharmacokinetics of bisphosphonates 
 
       The extraction of the BPs is not easy from biological fluids as all of them are 
known to be very polar compounds. Moreover most of them do not include a 
chromophore, and it creates a difficulty upon building a proper sensitive analytical 
method 
[47]
. For instance, applying a simple detection method for the measurement of 
BPs, such as radio-labelling, is not suitable due to the case of radiation limitations of the 
compounds used in such methods. Chromatographic methods developed for direct 
measurements of BPs, such as gas chromatography (GC) and high performance liquid 
chromatography (HPLC), are also not sensitive enough to detect BPs in serum longer 
than 24h in any case 
[48]
. As BPs are excreted, unaltered from the kidney, they can be 
detected in urine.  
 
      One of the most well-known characteristic properties of BPs is the low oral 
bioavailability that they have. The reason for the low oral bioavailability is the high 
ionization at physiological pH which makes them very polar and poorly absorbed from 
gastrointestinal (GI) tract 
[49]
. The oral bioavailability of the BPs is variable but is very 
similar between the NBPs. It is also known that approximately 50% of the absorbed 
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drug is permissively taken up by the skeleton and the rest which unaltered in 
metabolism yet, is excreted by excretory system in urine 
[48]
. Comparing the drug 
concentrations in plasma or in urine after drug uptake may be helpful to figure out how 
good the bioavailability of the drug is. The bioavailability of the drug can vary in both 
animals and humans and this can be seen in the table below (Table 1).  It is essential to 
know about the amount of BP at the skeleton when taking a close look at 
pharmacokinetics of BPs related with pharmacodynamics. Because BPs exert their 
action at the bone surface, where they are taken up by the osteoclasts during bone 
resorption 
[48]
. 
    
Table 1. Bioavailability of the BP drugs in rats and humans. 
 Human 
(%) 
    Rat 
    (%) 
  
Clodronate 1-2 
[50]
 - 
Etidronate 3-7 
[51]
 2.8-3.6 
[52]
 
Pamidronate                    0.3-0.48 
[53, 54]
 0.5-0.6 
[55]
 
Alendronate    0.7 
[56]
 0.9 
[57]
 
   
     
       There are some parameters that effect on absorption; one of them is the 
complexation with cations, such as Ca
2+ 
and Mg
2+
. The complexation between BPs and 
cations might hinder the absorption properties as BPs are strong chelating agents and 
they form complexes which have high molecular weight and tendency to precipitate 
easily 
[58, 59]
. These complexes are also insoluble 
[49]
. Thus the complexes may widen the 
paracellular tight junctions 
[60]
. If a higher dosage is provided, then the bioavailability of 
the drug may be increased but then it might cause also some subsequent local side 
effects 
[61]
. For instance, when the dose of ALN was increased from 2 to 40 mg orally, a 
better result was obtained in the bone of rats, which reflects an increase in the extent of 
drug absorption at high doses 
[62]
. Therefore, the oral absorption and the bioavailability 
of the BPs are dose-dependent parameters.  
       There are two routes for drug compounds to be taken into the blood stream, 
transcellular and paracellular 
[61]
. Transcellular transport, known as a transport in which 
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the compounds cross the epithelial barriers via biological membranes, is prevented by 
the hydrophilicity of BPs. Also the charge of BPs plays a role on this prevention. 
Therefore the paracellular route is the only way for BPs to be absorbed
 [63, 64]
. In the 
paracellular transport, drug compounds reach the bloodstream via the tight junctions 
between the epithelial cells. As the tight junctions are transparent to the molecules with 
the molecular weight up to 150 g mol
-1 [62]
 the BPs having large molecular size hinder 
the paracellular transport due to the selectivity controlled by the negative charge of 
brush-border membrane 
[65]
. Hence this evidence actually shows that also 
physicochemical properties of BPs are crucial. 
       From the bloodstream, BP is rapidly and easily taken up by the skeleton, however, 
the amount of BP taken up depends on couple of parameters, such as the affinity of the 
BP for bone mineral, renal function and prevalent rate of bone turnover 
[48]
. Saturation 
in binding sites of the skeleton is virtually impossible with the amounts of BP given in 
the treatment of osteoporosis and usually the capacity of the skeleton to retain is very 
high 
[66]
.  
       Half-lives of BP do not actually show whether its bone uptake is well. A fully 
comparable research is needed on half-lives of the BPs in order to make sense on results 
as different design of studies, analytical methods and pharmacokinetics techniques 
makes the comparison between studies difficult 
[67]
. The bioavailability of drug 
compound may be observed and drug concentration in plasma may be estimated by this 
way. A study on relative content of 
14
C-labelled ALN and RIS in humans receiving 
ALN 70 mg once-weekly or RIS 35 mg once-weekly has been performed over 10 years 
ago 
[68]
. In this study, retention carried out at 24 h by ALN was 54.5%. This value for 
RIS was 51%. There was no significant difference between them in this step. The only 
difference appeared after 72 h was that less RIS than ALN had been retained by the 
values of 45.5% and 51.8%. After 27 days of use, the retention values were 45.9% and 
33.8% for ALN and RIS, respectively. It has also been shown that the release of BP 
from bone is very slow 
[69]
. For instance, labeled PAM was detected in urine samples of 
young patients approximately 8.5 years after halt of treatment. There have been also 
several studies based on changes in bone mineral density (BMD) to the anti-fracture 
efficacy of inhibitors of bone turnover and of BPs especially 
[70, 71]
. An example of these 
studies is shown in following figure (Figure 4) 
[67]
. It is proposed that there are at least 
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two different processes based on the changes in BMD related with BP therapy 
[11]
. One 
of these processes proposes that the significant increase occurring in BMD in a few 
months is expected to result from filling in of “remodeling space”. The other one 
proposes on that the slower increases occurring after months and years are probably 
because of the increased mineralization of the existing bone being renewed slowly by 
body. This bone becomes older by the time passing and thus it then becomes more 
heavily mineralized.  Furthermore, it is also thought that the relationship between the 
increase in BMD with the various BPs and the related decreases in fractures is not very 
simple. 
        
Figure 4. Schematic presentation of bisphosphonate-induced changes in bone formation 
and resorption (right panel) and in bone mineral density of the spine (LS BMD, left 
panel) in osteoporosis. 
 
1.7 Use of bisphosphonates 
 
 
       BPs have been used in many different fields so far, firstly as corrosion inhibitors 
and complexing agents in industry 
[5]
. After the discovery of their abilities in 
pharmaceutical fields over 40 years ago, BPs could also be applied to the treatment of 
bone diseases as they have a high affinity to HAP 
[72]
. Their abilities in the vast field of  
pharmaceutical chemistry, have been widened by several investigations on the treatment 
of osteoporosis, Paget’s disease, osteolytic and metastatic bone diseases, pediatric bone 
diseases and hypercalcemia related diseases 
[73, 74, 75, 76, 77, 78, 79, 80, 81]
. Nowadays, uses of 
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the BPs can be divided into two groups, medical applications and non-medical 
applications of BPs. In this section, it will be focused on the medical applications 
related with bone diseases.  
 
1.7.1 Known medical applications of bisphosphonates 
 
       BPs have played a significant role in medical applications based on the treatment of 
various diseases since they were firstly discovered 
[5, 26]
. Most of the diseases treated by 
BP drugs are based on variation of activity of the osteoclasts 
[82]
. Among the clinical 
applications of BPs, the inhibition of bone resorption is the most impressive one as there 
was no effective treatment existed on that previously. Therefore, BPs have been a good 
option for the treatment of the diseases in which excessive osteoclast activity is a 
significant parameter. Nowadays, a number of BP-drugs are pharmaceutically available 
for several treatment methods concerning different bone diseases (Table 3). They are 
briefly explained in this section. 
 
Table 3. Most applicable BP-drugs in clinical use and their structures 
Bisphosphonates R1 R2 
   
Clodronate -Cl -Cl 
Etidronate -OH -Me 
Pamidronate -OH -CH2CH2NH2 
Alendronate -OH -((CH2))3NH2 
Risedronate -OH -CH2-3-pyridine 
Tiludronate -H -CH2-S-phenyl-Cl 
Ibandronate -OH -CH2CH2N(CH3)(pentyl) 
Zoledronate -OH -CH2-imidazole 
 
Etidronate 
 
       ETI is a salt of etidronic acid (Figure 5) which is a chelating agent. ETI was the 
first BP to be used in the treatment of osteoporosis. It is an effective BP to be used in 
the treatment of vertebral fractures. However there is no definite evidence for reduction 
of nonvertebral fracture
 [11]
. ETI has a low pharmacological potency. Surprisingly, ETI 
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(Figure 6) has been shown to include a relatively rapidly reversible effect on bone 
turnover. The Food and Drug Administration (FDA) approved ETI in 1977.  
              
Figure 7. Etidronate (left) and etidronic acid (right). 
 
 
Clodronate 
 
        CLO is a first-generation (non-nitrogenous) BP. Until recently, there has been no 
data on that if it is effective on fractures; however, in a few countries it has been 
approved for the treatment of osteoporosis 
[11]
. CLO (Figure 8) has a low cellular 
potency and low mineral affinity. 
 
Figure 9. Clodronate 
 
Alendronate 
 
ALN (Figure 7) is a well-known BP among second-generation BPs and is well 
established for the treatment of osteoporosis. It has a high mineral affinity and 
intermediate effects on FPPS 
[11, 83]
. Its effects do not appear to be as fast as in the case 
of RIS although it reduces all fracture types
 [11]
.  
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Figure 10. Alendronate.    
 
 
Pamidronate 
 
       There is not enough information about PAMs effects on fractures, however, it is 
being acceptable to be used in the treatment of patients who cannot tolerate oral BPs for 
osteoporosis. PAM (Figure 8) is being used to treat high blood calcium levels and some 
certain bone problems such as lesions and metastases in bones 
[48]
. It retards the release 
of calcium from bones to lower calcium levels 
[11]
.  
 
Figure 11. Pamidronate. 
 
 
 
Ibandronate 
 
       IBA (Figure 9) is meant for the treatment of osteoporosis in post-menopausal 
women. It is preferred that men should get a clinical test before uptaking IBA
 [84]
.  FDA 
approved IBA as a daily treatment for post-menopausal osteoporosis.  
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Figure 12. Ibandronate.        
 
 
Zoledronate 
 
       ZOL (Figure 13) is a third-generation BP developed exclusively for intravenous use 
rather than oral use. ZOL retards the bone resorption. The once yearly dosing regimen 
makes the chemistry in the period of clinical convenience. ZOL has an appreciable high 
affinity to bone mineral
 [11]
. ZOL is contraindicated for the patients having the case of 
pregnancy, poor renal function, hypocalcemia, paralysis and it can be helpful for 
treating pain caused by bone metastases
 [85]
. 
 
Figure 14. Zoledronate. 
 
Risedronate 
 
       RIS (Figure 15) is one of the strongest inhibitors of FPPS among the BPs based on 
clinical use 
[11]
. Although RIS has markedly lower mineral binding affinity comparing 
with that ZOL and ALN have. Use of RIS is a noteworthy as it may cause esophageal 
ulcers if it lodges in the esophagus. It is usually recommended that RIS should be taken 
with the body upright and possibly with a glass of water 
[86]
.  
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Figure 16. Risedronate. 
 
 
Tiludronate 
 
      TIL (Figure 17) has a wide clinical use especially for treatment of Paget’s disease. 
However, it has no significant development for osteoporosis 
[11]
. TIL acts via the 
incorporation into ATP metabolites, but not through the FPPS mechanism. 
 
Figure 18. Tiludronate. 
 
1.7.2 The effects of bisphosphonates on the treatment of bone diseases 
 
       Exploration of BPs as inhibitors of calcification made the scientists take some new 
steps through the bone diseases 
[74, 87]
. BPs were first applied to the treatment of Paget’s 
disease and the diagnosis of metabolic bone disease by complexation with 
99m
Tc 
[88, 12]
. 
However the BPs are nowadays most widely used for the treatment of osteoporosis 
which is thought as a major health problem for humans and especially for menopausal 
women 
[89]
. 
       Osteoporosis is a skeletal disease and it is characterized by reduction in bone mass 
that leads to an increased fracture risk 
[90, 91]
. Since early 1970s, BPs have been 
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investigated for the treatment of osteoporosis 
[92, 93]
. BP-drugs have the licensed positive 
effect in increasing BMD and on bone resorption and are taken by millions of patients 
worldwide. In the late 1980s, ETI became the first BP approved for the treatment of 
osteoporosis 
[94]
. In 1990, another successful study about use of ETI in a randomized, 
double-blind, placebo-controlled study in 66 postmenopausal women over three years, 
was published 
[95]
. The efficacy of ALE and other BPs in postmenopausal women was 
proved by several studies 
[96, 97, 98, 99, 100]
. Clinical studies proved that all approved BPs 
actually reduced the fracture risk in bone. However, some of them were more efficient 
comparing with the others in preventing the fractures in different parts of body. For 
instance, ALN, ZOL and RIS are more efficient than IBA in preventing hip fractures 
[101]
.  
       Paget’s disease is a chronic disorder in which bone turnover of one or several bones 
is increased, resulting in enlarged and weak (misshapen) bones. This type of bone 
disease appears in approximately 3% of people above the age of 40 
[102]
. Since the main 
point of the disease is the increased bone resorption, BPs are currently being used for 
the treatment of Paget’s disease [103, 104]. So far, a number of studies have proved that 
BPs in the management of patients with Paget’s disease, are efficient and the 
availability of more potent, newer, BPs has improved treatment consequences 
[75, 105, 106, 
107, 108, 109, 110, 111, 112]
.  
        The BPs tested in patients with problems based on bone metastases, have shown 
reduced skeletal complications, such as reduction in osteolytic progression, fractures 
and bone pain 
[113]
.  Additionally, almost 30% of cancer patients have also 
hypercalcemia during their disease. Hypercalcemia occurs in the malignant stage and is 
a very serious complication. Increased osteoclast activity causes a high release of bone 
calcium and it results to hypercalcemia 
[114]
.  In the medication step of this disease, 
especially ZOL, PAM and CLO showed impressive efficacy towards the treatment of 
hypercalcemia of malignancy 
[80, 115, 116]
. Osteoclast activity plays a significant role in 
bone metastases 
[113]
. BP-drugs are strongly recommended for the treatment of 
metastatic bone disease. 
       One of the most common uses of BPs is for bone imaging with radiochemicals 
[5, 
117]
. The application of BPs as bone scanning agents may depend on their ability to be 
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combined with a gamma-emitting technetium isotope 
[88, 118, 119]
. This ability provides 
such complexes proper locations in the sites of bone turnover
 [120]
. The single-photon 
emission computed tomography (SPECT) is a widely used technique with gamma-
emitting BP complexes. Technetium-99m (
99m
Tc) isotope is the most widely used 
radionuclide with this method since its suitable nuclear properties (half-life, T1/2= 
6.0067 h) and this isotope is then transformed into stable technetium-99 by nuclear 
transformation 
[121, 120]
. These gamma-emitting BP complexes are nowadays leading the 
rest used in bone imaging since they have high sensitivity, good results and low cost 
[122, 
123]
.  
       The BPs have also antitumor 
[124]
, anti-inflammatory effects 
[125, 126]
 as well as 
effects on osteolytic bone disease of multiple myeloma 
[127, 128]
. A summary of BP’s 
biomedical applications is shown in following figure (Figure 13) 
[72]
.  
Figure 13. Biomedical applications of BPs. 
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1.8 The mechanism of action of bisphosphonates in cells 
 
      
       Osteoclasts are the cells that cause the resorption of bone tissue 
[5]
. Osteoclasts are 
organized to support the massive transport of protons for the solubilization of the HAP 
and the acidification of the resorption part 
[129, 130]
. Bone tissue is a porous structure 
which contains a solid matrix, cells and a fluid phase 
[131]
. BPs have been used for over 
50 years 
[37, 132]
. The studies on it have shown that BPs can affect the bone resorption 
caused by osteoclasts in many ways 
[133, 134]
.  
 
       BPs are internalized via endocytosis by the osteoclasts during the bone resorption 
[133]
. Due to accumulation type of the BPs in bone, they have a close contact to 
osteoclasts rather than other cells in bone 
[135]
. The action of vacuolar-type proton 
pumps in the osteoclast ruffled membrane causes an acidification to the sub-cellular 
space beneath the osteoclast during the bone resorption 
[136]
. This acidification initiates 
the dissolution of the HAP bone mineral and it results in their accumulation and up-take 
by fluid-phase endocytosis 
[137, 138]
. It is also known that BPs have significant effect 
especially on mature osteoclasts. These mature osteoclasts are formed by the fusion of 
mononuclear precursors of haematopoietic origin 
[5]
. By preventing and reducing the 
activity of osteoclasts which cause the resorption in bone, or by increasing the apoptosis 
rate of them, BPs inhibit the resorption in bone caused by osteoclasts 
[16]
.  
 
         
1.8.1 Effects of Bisphosphonates on Osteocytes 
 
       Osteocyte (Figure 14) is a cell characteristic of mature bone tissue and that lies 
within the substance of fully formed bone 
[139]
. It is derived from osteoprogenitors, a 
fraction of which differentiate into active osteoblasts. It is also known that mature 
osteoblasts may also acquire a resting phenotype becoming a lining cell 
[131]
. Osteocytes 
are the most commonly found cells in bone 
[140, 139]
 and the surface area within the 
osteocytic network is approximately 1000-5000 m
2 [141]
. This canalicular structure 
allows the drugs to access 
[15]
.  
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       Several BPs in very low concentrations can protect osteocytes against apoptosis 
[142, 
143]
. The inhibion made by BPs over the osteocyte apoptosis arises to be mediated 
through the activation of extracellular signal-regulated kinases (ERKs) and opening of 
connexin 43 hemichannels 
[144]
. BP effects on osteocystes are supported by the results of 
the pharmacological studies based on transgenic animals, especially on their ability to 
prevent the apoptotic effects of glucocorticoids 
[145]
 or cyclic mechanical loading 
[146]
. 
Experimental findings show that the potency of BPs on osteocytes doesn’t state about 
their effects on osteoclasts 
[147]
. Hence it is also proposed that BPs having little anti-
resorptive activity might have ability to increase osteocyte survival 
[148]
. 
 
 
Figure 14. Evolution of osteocytes 
[149]
. 
  
 
1.8.2 Effects of Bisphosphonates on Osteoblasts 
 
 
       Osteoblast is a cell which bone develops from and is a mononuclear specialized 
derivation of mesenchymal stem cells 
[150, 151]
. Osteoblast functions in groups of 
connected cells and is involved in osteoclast regulation 
[152, 153]
. Recent studies on 
osteoblasts also showed that they may play a significant role on bone disorder, such as 
Paget’s disease and osteoporosis [151].  
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       It was proven in the 1990s that the osteoblasts treated with BPs can inhibit 
osteoclastogenesis 
[154]
. Clinical studies verified that BPs have a mitogenic effect over 
the osteoblasts 
[155, 156]
. Other studies proposed that BPs could inhibit the expression of 
receptor activator of nuclear factor-ĸB ligand (RANKL) also known as tumor necrosis 
factor ligand superfamily member 11 (TNFSF11) and could also increase the expression 
of osteoprotogerin (OPG) in osteoblastic cells of human 
[157]
. It is also known that 
osteoblast effect on RANKL signaling mediates the antiresorptive effect of BPs 
[158]
. 
Furthermore, some other studies have demonstrated that BPs with different 
concentrations can decrease or increase osteoblastogenesis depending on their 
concentration 
[156, 159, 160]
. A recent study on BP effects on osteoblasts proposed that as 
the osteoblasts may be involved in bone disorders such as Paget’s disease and 
osteoporosis, it is basically imaginable that BPs play a role in these diseases 
[151]
. 
However, the observed effects of BPs mentioned above differ with the type of BP used 
in the model system and the method used 
[161]
. 
 
1.8.3 Effects of bisphosphonates on hydroxyapatite (HAP) 
 
       Chemical formula of HAP is Ca10(PO4)6(OH)2 
[162]
. HAP is one of the most studied 
biomaterials as it is structurally related with bone mineral 
[163]
. A close analog of this 
compound, a biological apatite, constitutes the bone mineral 
[162]
. BPs possess high 
affinity for HAP so that BPs have ability to bind to HAP 
[72]
. As a result of binding to 
HAP, BPs are easily taken up by bone 
[137]
.  
 
       Long time ago it was approved that BPs have multiple effects on HAP such as, 
inhibititon of crystal dissolution and inhibition of the aggregation of crystals 
[11, 38, 164]
. 
The amount of BP attached to HAP can be predicted by a Langmuir adsorption isotherm 
[11]
. It was also proven that the classical adsorption isotherms are leading to binding 
characteristics. Hence it is known that a saturation level on the amount of BP bound 
demonstrates about the capacity of crystals for adsorbing a given BP onto their surface 
[11]
. Additionally, a recent chromatographic study showed that BPs differ in their 
retention time for their binding ability to HAP 
[165]
. For instance, ALE and ZOL showed 
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significantly longer duration times than RIS. Furthermore, it is also known that small 
differences on R1 and R2 groups, can enhance the binding to HAP as mentioned before 
in the chapter of structure-activity relationships of BPs. Even though there is still a lack 
of clear information on these biologically important issues, the findings on BPs’ ability 
to bind to HAP can be used for pro-drug studies 
[166, 42]
.  
      
1.9 Side effects of use of bisphosphonate-drug 
 
       BPs have some side effects which usually last in a short while. As everyone reacts 
to drugs in a different way, there might be a chance to have one or more of possible side 
effects. These possible side effects are listed below 
[167, 168]
. 
Table 4. Side effects of BP use and its possible solutions. 
Side Effect Simple solution 
Fever or flu Taking paracetamol can help. 
Hypocalcaemia(low level of calcium 
concentration in blood) 
Blood test based on checking the levels of 
minerals first, then medication might help also. 
Bone and joint pain A mild painkiller such as paracetamol may help. 
Change in bowel 
mechanism(constipation or diarrhoea) 
Drinking fluids (6-8 glasses per day). 
Feeling sick (nausea) It is a temporary feeling and lasts in a few days. 
If it continues or gets worse, doctor can 
prescribe an anti-sickness tablet. 
Damage to kidney Regular blood test is needed in order to check 
how well the kidney works. 
Osteonecrosis of the jaw If BP is taken for longer than a year, a dental 
check-up is needed before treatment starts. 
        
       According to a recent study, among the side effects of BP use, the most frequent 
one was GI discomfort appearing 19.8% of the patients on medication 
[169]
 while other 
studies found it as 25%
 [170]
  and 20.8% 
[171]
, respectively. In another study it was also 
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reported that the patient who suffered from GI side effects had poor acquiescence to the 
treatment progress 
[172]
. 
       As the tolerance of any patient for any drug is different, side effect topic is very 
wide and might not be understood or generalized easily. 
 
1.10 Future prospects on bisphosphonates 
 
       Even though there have been many discussions on the treatment way of bone 
diseases with BPs, the clinical use of BP in this matter is being very well studied 
[5]
. 
Additionally, there are also remarkably successful experimental studies and 
observations about mortality reducing ability and anti-cancer effects of BP drugs 
[173, 174]
 
as well as other effects of them as mentioned before in previous chapters. But almost all 
of these studies have also their own issues such as, the optimal duration of therapy, 
gender, oral versus intravenous therapy, which means that there might be a need of 
further studies on such issues.       
       The idea that BPs might be used as carriers to deliver some other pharmacological 
agents to the bone was achieved before 
[175]
. It has also given a future prospect based on 
that to release different active drugs via BP conjugates to the target organs or tissues in 
human body.  
       In addition to current uses of BP, a recent study has proven that BPs have shown a 
positive effect to inhibit arterial calcification 
[176]
. However there is still a further 
research needed on recruiting these promising studies. 
       Beside all of these, there are still a lot of studies to be done on BP effects on the 
treatment methods of several diseases as well as endless future prospects in which the 
BPs can be used. In this case, it might be thought that knowing more about the 
mechanism of action of BP drugs in human body, may give more opportunities to 
scientists to build up brand-new ideas to overcome some of major diseases for humans 
[177]
. In the following figure, future prospects of BP are summarized 
[5]
 (Figure 15).  
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Figure 15. Future ideas for BPs. 
 
1.11 The aim of the study 
 
       The literature part of the thesis is intended to explain about general knowledge and 
aspects related with the main properties, medical applications, the mechanism of action 
and future prospects of BPs. 
 
       The purpose of present study is based on the synthesis of novel bifunctional BPs 
and their conjugation with PAs. By this investigation, synthetic pathway and potential 
problems of the synthesis of (2-((2-((2-aminoethyl)amino)ethyl)amino)ethane-1,1-
diyl)bis(phosphonicacid) and (2-((2-aminoethyl)amino)ethane-1,1-
diyl)bis(phosphonicacid) were learnt. This study also aims to give an aspect on the 
synthesis of these BP-PA conjugates and the difficulties observed during this project.  
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2 Experimental Part 
 
2.1 Novel bisphosphonate and polyamine conjugates 
 
       PAs are a class of the compounds containing two or more primary amino groups 
[178]. They exist in all eukaryotic cells with their concentrations in mM range. 
Biochemically the term polyamines means the naturally occurring PAs, spermidine 
(SPD), putrescine (PUT) and spermine (SPM) which are essential for growth 
[179]
. They 
are found in vegetables and fruits, fermented food products (yoghurt, beer), foods of 
animal origin (milk, fish, eggs and meat). 
 
       PAs have also several synthetic derivatives, such as triethylenetetraamine (TRIEN) 
[180]
. TRIEN (Figure 16) is a selective chelator for Cu
2+
 and also for other ions. It is used 
as an alternative treatment in Wilson’s disease, an autosomal recessive disorder of 
copper metabolism, where the excessive copper accumulation leads to several 
neurological and mental problems. 
 
 
 
Figure 16. Triethylenetetraamine.  
 
       Although there have been separately many publications on both PAs and BPs, there 
has been only some studies based on BP-PA (Figure 17) conjugates 
[181]
.  BP-PA 
conjugates could possibly be used as selective chelating agents. In medicine, they could 
potentially be used as imaging agents when combined with radioisotopes, such as 
99m
Tc. 
These new conjugates might have also interesting metal chelating abilities 
[4]
. 
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Figure 17. The basic structure of novel polyamine bisphosphonate conjugate. 
 
 
2.2 Materials and Method 
 
2.2.1 General  
 
The main method used for observation and analysis of both the reaction and the 
compounds obtained, was 
1
H, 
31
P and 
13
C NMR spectroscopy.  The NMR 
measurements were carried out on a Bruker Avance 500 DRX instrument with working 
frequency of 500.1 Hz, 202.4 Hz, and 125.7 Hz for 
1
H, 
31
P and 
13
C nuclei respectively. 
NMR spectra were obtained with internal standards, tetramethylsilane (TMS) in CDCl3 
and sodium 3-(trimethylsilyl)-1-propanesulfonate (TSP) in D2O. When required and 
possible, thin layer chromatography (TLC) method was used for the purity evaluation 
and observation with KMnO4 and Ninhydrin. All the compounds involved in this 
research, are named based on the software of Chembiodraw 13.   
 
2.2.2 Materials 
 
Both solvents and dry solvents in reactions were used as they are supplied. 
Tetraisopropyl-methylenebisphosphonate (98%) was used as prepared before. 
Tetraisopropyl-ethenylidenebisphosphonate was prepared according to known methods 
published by Degenhardt et al. 
[182]
 and the purity was not less than 99% obtained by 
NMR. Paraformaldehyde (95%), di-tert-butyldicarbonate (98%) and 
Ethyltrifluoroacetate (99%) were supplied by Fluka, diethylamine (99,5%) and 
diethylenetriamine (99%) were supplied by Sigma-Aldrich, ethylenediamine (98%), 
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magnesium sulfate and potassium carbonate were supplied by J.T Baker. 
Toluenesulfonic acid (99%) was supplied by Merck. Tert-butyl (2-aminoethyl) 
carbamate (3b) was prepared according to the literature in the methods published by J. 
Chadwick et al. 
[183]
 and tert-butyl(2-aminoethyl)(2-((tert-butoxycarbonyl)amino)ethyl) 
carbamate (4b) was prepared according to known methods published by M. Carland et 
al. 
[184]
. For the methodical column chromatography, Silica gel 60 (supplied by Merck) 
was used. TLC was accomplished using Merck TLC aluminium plates (Silica gel 60 
F254, 20x20) and observation by staining on them was enhanced with iodine and 
potassium permanganate. 
 
 
 
 
31 
 
2.2.3 Prepared compounds 
 
The general aspect of the research carried out in this thesis is shown in following scheme (Scheme 1).  
 
 
 
R1 (iso-propyl group) = C3H7 
Scheme 1. The pathway of reactions in current study. 
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Tetraisopropyl ethenylidenebisphosphonate (2) 
Paraformaldehyde (6.78 g, 225 mmol) and diethylamine (3.35 g, 45 mmol) were 
combined in 100 ml of dry methanol and the mixture was warmed until it got clear. 
Then heat was removed and afterwards compound 1 (12.3 g, 35 mmol) was added into 
the mixture. Then the mixture was refluxed for 6 days. Afterwards it was concentrated 
under reduced pressure. 20 ml of dry toluene was then added and the mixture was 
concentrated. This step was repeated twice in total to ensure complete removal of 
methanol from expected intermediate (CH3OCH2CH(PO3i-Pr2)2) which was obtained as 
a clear liquid. This intermediate was dissolved in 100 ml of toluene and afterwards 
catalytic amount of toluenesulfonic acid (monohydrate) was added. In a Dean-Stark 
trap, methanol was removed by refluxing over night. After refluxing, the mixture was 
concentrated under reduced pressure. Compound 2 was obtained as a clear liquid. 
Column chromatography was carried out on the compound (silica gel, 1:1 
acetone/hexane). Compound 2, yield 3,461 g : 
1
H NMR (CDCl3) δ 7.0- 6.8 (m, 2H, 
H2C), 4.9-4.6 (m, 4H, OCH), 1.6-1.2 (m, 24H, CH3); 
13
C NMR (CDCl3) δ 147.3 (s, 1C, 
=CH2), 135.1 (t, 1C, PCP, 
1
JCP=168.34), 71.62- 71.29 (m, 4C, OCH), 24.415-23.85 (m, 
8C, CH3);  
31
P NMR (CDCl3) δ12.22. 
 
Tert-butyl(2-aminoethyl)carbamate (3b) 
A solution of di-tert-butyl dicarbonate (1.4 g, 6 mmol) in anhydrous 1,4-dioxane (50 
ml) was added over 3 h to a stirring solution of ethylenediamine (2,12 g, 35 mmol) in 
1,4-dioxane (50 ml). After stirring overnight the solvent was removed under reduced 
pressure. Afterwards 70 ml of water was added to the residue and the insoluble bis-
substituted product was collected by filtration. The filtrate was extracted with CH2Cl2 
(5x20 ml). The organic extracts were dried over Na2SO4, filtered and concentrated 
under reduced pressure to give compound 3b. The compound was synthesized with a 
different starting material, ethylenediamine was used instead of 1,4-diaminobutane 
mentioned in original paper. Compound 3b (purity 74%) yield 0.43 g : 
1
H NMR 
(CDCl3) δ 4.9 (s, 1H, NHBOC), 3.3-3.1 (m, 2H, CH2), 2.9-2.7 (m, 2H, CH2), 1.6-1.4 
(m, 9H, CH3); 
13
C NMR (CDCl3)  δ 156.6 (s, 1C, C=O),  79.44 (s, 1C, CH), 42.22 (s, 
2C, CH2), 28.7 (s, 3C, CH3). 
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Tert-butyl(2-((2,2-bis(diisopropoxyphosphoryl)ethyl)amino)ethyl)carbamate (3c) 
In order to combine protected amine and bisphosphonate groups, compound 3b (1.0 eq. 
, 44 mg, 0.085 mmol) and compound 2 (1.0 eq. , 100 mg, 0.28 mmol) in 25 ml of 
acetonitrile, were taken into a flask. The mixture was refluxed for 2h. According to 
spectra result, 73 mg of compound 3b was added in order to react with unreacted 
compound 2. Then the mixture was refluxed for 1h and concentrated under reduced 
pressure to give 3c. Compound 3c (purity 90%) yield 197 mg : 
1
H NMR (CDCl3) δ 
4.86-4.7 (m, 4H, CH), 3.24-3.14 (m, 2H, CH2), 3.1 (td, 2H, 
3
JHP=17.55 Hz, 
3
JHH=5.5 Hz, 
CH2), 2.7 (m, 2H, CH2), 2.44 (tt, 1H, 
2
JHP=23.76 Hz, 
3
JHH=5.5 Hz, PCH), 1.5-1.25 (m, 
33H, BOC + i-Pr groups); 
13
C NMR (CDCl3) δ 156.4 (s, 1C, C=O), 78.8 (s, 1C, OC), 
72-70.7 (m, 4C, OCH), 48.32 (s, 2C, CH2), 45.33 (s, 1C, CH2), 39.3 (t, 1C, J=134.6, 
PCP), 28.5 (s, 3C, CH3), 24.6-23.8 (m, 8C, CH3);  
31P NMR δ 21.94.  
 
(2-((2-aminoethyl)amino)ethane-1,1-diyl)bis(phosphonicacid) (3d) 
Compound 3c (150 mg, 0.29 mmol) in 25 ml of HCl (4M) was refluxed for 1h and then 
stirred for 20 minutes. Then the mixture was concentrated under reduced pressure to 
give compound 3d. Compound 3d (purity 67%) yield 99 mg : 
1
H NMR (D2O) δ 3.65-
3.4 (m, 6H, CH2), 2.85-2,7 (m, 1H, CH);  
13
C NMR (D2O) δ 45.66 (s, 1C, CH2) 44.76 
(s, 1C, CH2), 41.93 (t, 1C, J=123.72, CH), 35.92 (s, 1C, CH2); 
31P NMR δ 16.82. 
 
Tert-butyl(2-aminoethyl)(2-((tert-butoxycarbonyl)amino)ethyl)carbamate (4b) 
Diethyltriamine (1 g, 9.69 mmol) was dissolved in 40 ml of methanol. Reaction mixture 
in a flask was placed into a liquid nitrogen and methanol bath at -78°C.  Then ethyl 
trifluoroacetate (1.37 g, 1.0 eq.) mixed with 10 ml of methanol, was added into the 
mixture. The mixture was kept in the bath for 1h and then taken to an ice bath at 0°C. 
Afterwards, di-tert-butyl dicarbonate (8.46 g, 4.0 eq.) mixed with 6 ml of methanol was 
added into the mixture and the mixture was kept at 25°C over night. Then the mixture 
was concentrated under reduced pressure to give 4b. Compound 4b, yield 1.872 g : 
1
H 
NMR (CDCl3) δ 5.9-5.6 (m, 1H, NH), 3.35-3.18 (m, 8H, CH2), 1.56-1.33 (m, 18H, 
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NHBOC, NBOC); 
13
C NMR (CDCl3) δ 156.4 (s, 2C, C=O), 79.54 (s, 2C, C(CH3)), 
51.35-41.12 (m, 8C, CH2), 28.8 (s, 6C, CH3) 
 
Tert-butyl(2-((2,2-bis(diisopropoxyphosphoryl)ethyl)amino)ethyl)(2-((tert-
butoxycarbonyl)amino)ethy)carbamate (4c) 
Compound 2 (100 mg, 0.28 mmol) and compound 4b (85 mg, 0.28 mmol) were taken 
into a flask and then 25 ml of acetonitrile was added. Then the mixture was refluxed for 
1h and then concentrated under reduced pressure. Compound 4c, yield 178 mg : 
1
H 
NMR (CDCl3) δ 4.85-4.7 (m, 4H, CH) 3.4-3.2 (m, 8H, CH2), 3.12 (td, 2H, 
3
JHH= 5.39, 
3
JHP= 16.32, CH2), 2.7-2.6 (broad-s, 1H, NH), 2.58-2.37 (m, 1H, CH), 1.5-1.39 (m, 24H, 
CH3), 1.38-1.27 (m, 18H, NHBOC, NBOC);  
13
C NMR (CDCl3) δ 156.5 (s, 2C, C=O), 
48.8-38.05 (m, 5C, CH2), 29.4 (m, 6C, CH3), 25.26-23.53 (m, 1C, CH); 
31P NMR δ 
21.79. 
 
(2-((2-((2-aminoethyl)amino)ethyl)amino)ethane-1,1-diyl)bis(phosphonic acid) (4d) 
Compound 4c (178 mg, 0.27 mmol) in 25 ml of HCl (4M) was refluxed for 1h. Then the 
mixture was concentrated under reduced pressure to give 4d. Compound 4d (purity 
63%) yield 107 mg : 
1
H NMR (D2O) δ 3.5-3.2 (m, 8H, CH2), 2.7-2.56 (m, 2H, CH2), 
2.55-2.42 (m, 1H, CH); 
13
C NMR (D2O) δ 46.15-43.86 (m, 5C, CH2), 36.94 (t, 1C, 
1
JCP= 121.33, PCP); 
31P NMR δ 16.08. 
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2.3 Results and Discussion  
 
        The studies on preparing the BP-PA conjugates desired (Scheme 1) was initiated 
by the easiest starting point, ethenylidenebisphosphonate (2). This starting point allows 
Michael addition to be carried out on the double bond in structure of 2 for conjugation 
reaction between PA and BP 
[181, 182]
.  
       The first step through the current study was taken via the purification of compound 
1 by vacuum distillation. In an uneventful manner, expected fraction (the purest of 1) 
was collected with the purity of 96.7% at the temperature range of 60-110°C (1 mmHg). 
Following step was to convert the BP tetraester, 1, into 2 by the known method 
[182]
.  
Compound 2 was obtained without difficulties but due to the impurities not desired, 
column chromatography method was applied for purifying 2. Afterwards, the fractions 
which have the purities over 95% were collected to be used for further steps. 
       In the next step Boc protected PA, 3b, was prepared by the known method 
[183]
. 
Ethylenediamine (EDA), 3a, was used as a starting material instead of 1,4-
diaminobutane mentioned in the method. In this step 3b was successfully synthesized. 
The only problem in the process was about separation of organic extracts with CH2Cl2. 
Sometime also water phase was analyzed and extraction process was done for the 
second time over it in order to obtain a better yield. The development in extraction 
process might give desired organic phase immediately at once, but then also the 
conditions should be optimum for it. 
       Afterwards compound 3b was conjugated to 2 by using Michael type addition. The 
optimum solvent used in this reaction was acetonitrile as it showed the best activity and 
provided the best result and environment among the solvents used (Table 5) for the 
purity of 3c. Typical problem faced in this step was the case when all of 2 was reacted, 
there was still unreacted 3b. This unreacted PA problem was solved by adding a 
calculated amount of 2 according to 
1
H NMR spectra corresponding to the result of the 
reaction. Eventually the intermediate compound, 3c, was successfully synthesized after 
refluxing in acetonitrile. 
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Table 5. The optimization of solvents used in conjugation of 2 and 3b and the purities 
of 3c compounds obtained.   
Solvent Name Purity observed by 
31
P NMR  (%) 
Acetonitrile 80 
DCM 38 
Diethyl ether 66 
Ethyl acetate 64 
Toluene 69 
 
       For obtaining one of the final products desired, 3d, both Boc protective groups and 
isopropyl groups of 3c were removed with acid catalysis hydrolysis. The acidic 
environment of mixture caused the reaction to go reverse. The amine group attached to 
the central carbon via a CH2 bridge detached due to the acid catalysis hydrolysis used 
for the cleavage of Boc and isopropyl groups. Thus compound 2 was unintentionally 
obtained after the cleavage of amine group. Then 2 reacted with water in acidic 
conditions and instead of the amine group desired, the OH group attaching to the side 
chain was observed. Therefore in 
31
P NMR spectra there were obvious three different 
peaks corresponding to 2, 3d and the compound (2- hydroxyethene-1,1-
diyl)bis(phosphonic acid) (Figure 18) which has OH group in its side chain. The 
existence of OH group in side chain was also proven by general 
1
H NMR spectra table. 
A purification method, crystallization with ethanol and water, on 3d slightly worked out 
and it developed the purity of the compound but was not as efficient as expected. 
Eventually 3d was successfully synthesized with some undesired impurities. 
    
       Compound 3c was also treated with TFA in order to remove Boc and isopropyl 
groups. But this attempt couldn’t be carried out to remove them out of 3c. It was 
observed clearly by 
31
P NMR that the reaction go reverse and there was still the peak 
corresponding to 2 and not to 3d. According to findings, it can be proposed that if 
optimum conditions for the cleavage with HCl or TFA are provided, then removal of 
both Boc and isopropyl groups might be smoothly carried out without such problems. 
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       Another Boc protected PA in the reaction pathway, 4b, was prepared from 
diethylenetriamine (DETA), 4a, by the known method 
[184]
. As a result 4b was 
successfully synthesized. The only problem faced in this step was about the third Boc 
group not desired to attach to DETA (Scheme 2) after removal of trifluoroacetamide 
protection at one of the amine sides of DETA. This problem was also proven by 
1
H 
NMR spectra as there was the peak corresponding to three Boc groups. The case further 
reactions were carried out successfully, showed that there was more 4b than the 
compound containing three Boc protective groups and this problem didn’t cause any 
important further issue for the pathway.    
 
Scheme 2. Trifluoroacetamide attaching to 4a, Boc protective groups attaching to 4a 
with trifluoroacetamide, an undesired compound containing three Boc groups (III) and 
the synthesis of 4b(IV).  
       In the next step 4b was conjugated to 2 by using Micheal type addition. Acetonitrile 
was the most efficient solvent among the solvents used for this conjugation reaction to 
be carried out, toluene, DCM, acetonitrile, respectively. The intermediate, 4c, was easily 
obtained after refluxing in acetonitrile without any problem.  
       In the last step acid catalysis hydrolysis was carried out on 4c in order to remove 
both Boc protective and isopropyl groups for obtaining the end product, 4d. Compound 
4c was treated with 4M HCl. As it was also observed in the cleavage of Boc and 
isopropyl groups of 3d, acidic environment caused the reaction go reverse in the case of 
4c. In the 
1
H and 
31
P spectra of 4d there were peaks corresponding to the structures of 
4d, 2 and the compound undesired (Figure 18) containing OH group in its side chain. 
Eventually 4d was obtained but with some impurities. By the crystallization with water 
and ethanol, the purity of 4d was developed to 63%. 
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Figure 18. An undesired impurity occured during the cleavage of Boc and isopropyl 
groups of the compounds, 3c and 4c. 
 
       All the prepared compounds in this study were identified by using 
1
H, 
13
C and 
31
P 
NMR spectroscopy methods of analysis. 2D 
1
H-
1
H COSY (homonuclear correlated 
spectroscopy), 2D 
13
C-
1
H HSQC (heteronuclear single quantum correlation 
spectroscopy) were used to identify the assignments of the signals on NMR spectra 
when needed.  
 
2.4 Conclusion  
 
        A method to synthesize (2-((2-((2-aminoethyl)amino)ethyl)amino)ethane-1,1-
diyl)bis(phosphonicacid) and (2-((2-aminoethyl)amino)ethane-1,1-
diyl)bis(phosphonicacid) was developed starting from tetraisopropyl 
ethenylidenebisphosphonate. 
                The yields mentioned in experimental part show that the reaction conditions 
are sub-optimal. Since the final compounds are not stable enough in acidic environment, 
they might not be used as imaging agents in medicine when combined with 
radioisotopes. But if it was possible to purify them and they were stable enough, then 
they might have interesting metal and selective chelating abilities as well as the 
tendency to be imaging agents.        
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